Shares of Basilea Pharmaceutica AG (OTCMKTS:BPMUF - Get Free Report) reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $47.50 and last traded at $47.50, with a volume of 10 shares changing hands. The stock had previously closed at $51.00.
Basilea Pharmaceutica Price Performance
The company has a debt-to-equity ratio of 5.70, a quick ratio of 3.27 and a current ratio of 4.10. The stock has a 50-day simple moving average of $52.58 and a 200-day simple moving average of $52.74.
About Basilea Pharmaceutica
(
Get Free Report)
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.
Further Reading
Before you consider Basilea Pharmaceutica, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Basilea Pharmaceutica wasn't on the list.
While Basilea Pharmaceutica currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
